Clinical Characteristics of Patients with Coronavirus Disease (COVID-19): Preliminary Baseline Report of Japan COVID-19 Task Force, a Nationwide Consortium to Investigate Host Genetics of COVID-19.


Journal

International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases
ISSN: 1878-3511
Titre abrégé: Int J Infect Dis
Pays: Canada
ID NLM: 9610933

Informations de publication

Date de publication:
Dec 2021
Historique:
received: 18 07 2021
revised: 24 09 2021
accepted: 24 09 2021
pubmed: 4 10 2021
medline: 15 12 2021
entrez: 3 10 2021
Statut: ppublish

Résumé

The coronavirus disease (COVID-19) pandemic is having a devastating effect worldwide. Host genome differences between populations may influence the severity of COVID-19. The Japan COVID-19 Task Force is conducting host genome analysis of hospitalized patients with COVID-19 from more than 70 institutions nationwide in Japan. This report describes the clinical characteristics of patients enrolled to date. The median (interquartile range) age of the 1674 patients included in the analysis was 59 (45-71) years, and more than half of the patients (66.2%) were male. Less than half of the patients (41.2%) had severe disease. The case fatality rate was 3.2%. Since this is a hospital-based study, the number of severe cases was relatively high, but the case fatality rate was relatively low, when compared to that of other countries. In the future, we will continue to enroll patients and conduct genome analyses of patients with COVID-19.

Sections du résumé

BACKGROUND AND DESIGN METHODS
The coronavirus disease (COVID-19) pandemic is having a devastating effect worldwide. Host genome differences between populations may influence the severity of COVID-19. The Japan COVID-19 Task Force is conducting host genome analysis of hospitalized patients with COVID-19 from more than 70 institutions nationwide in Japan. This report describes the clinical characteristics of patients enrolled to date.
RESULTS RESULTS
The median (interquartile range) age of the 1674 patients included in the analysis was 59 (45-71) years, and more than half of the patients (66.2%) were male. Less than half of the patients (41.2%) had severe disease. The case fatality rate was 3.2%.
CONCLUSIONS CONCLUSIONS
Since this is a hospital-based study, the number of severe cases was relatively high, but the case fatality rate was relatively low, when compared to that of other countries. In the future, we will continue to enroll patients and conduct genome analyses of patients with COVID-19.

Identifiants

pubmed: 34601141
pii: S1201-9712(21)00775-X
doi: 10.1016/j.ijid.2021.09.070
pmc: PMC8482546
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

74-81

Informations de copyright

Copyright © 2021 The Author(s). Published by Elsevier Ltd.. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Hiromu Tanaka (H)

Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan.

Ho Lee (H)

Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan.

Atsuho Morita (A)

Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan.

Ho Namkoong (H)

Department of Infectious Diseases, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan.

Shotaro Chubachi (S)

Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan.

Hiroki Kabata (H)

Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan.

Hirofumi Kamata (H)

Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan.

Makoto Ishii (M)

Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan.

Naoki Hasegawa (N)

Department of Infectious Diseases, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan.

Norihiro Harada (N)

Department of Respiratory Medicine, Juntendo University Faculty of Medicine and Graduate School of Medicine, Tokyo, Japan.

Tetsuya Ueda (T)

Department of Respiratory Medicine, Osaka Saiseikai Nakatsu Hospital, Osaka, Japan.

Soichiro Ueda (S)

JCHO (Japan Community Health Care Organization) Saitama Medical Center, Internal Medicine, Saitama, Japan.

Takashi Ishiguro (T)

Department of Respiratory Medicine, Saitama Cardiovascular and Respiratory Center, Kumagaya, Japan.

Ken Arimura (K)

Department of Respiratory Medicine, Tokyo Women's Medical University, Tokyo, Japan.

Fukuki Saito (F)

Department of Emergency and Critical Care Medicine, Kansai Medical University General Medical Center, Moriguchi, Japan.

Takashi Yoshiyama (T)

Fukujuji Hospital, Kiyose, Japan.

Yasushi Nakano (Y)

Kawasaki Municipal Ida Hospital, Department of Internal Medicine, Kawasaki, Japan.

Yoshikazu Mutoh (Y)

Department of Infectious Diseases, Tosei General Hospital, Seto, Japan.

Yusuke Suzuki (Y)

Department of Respiratory Medicine, Kitasato University, Kitasato Institute Hospital, Tokyo, Japan.

Koji Murakami (K)

Department of Respiratory Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan.

Yukinori Okada (Y)

Department of Statistical Genetics, Osaka University Graduate School of Medicine, Suita, Japan; Integrated Frontier Research for Medical Science Division, Institute for Open and Transdisciplinary Research Initiatives, Osaka University, Suita, Japan; The Center for Infectious Disease Education and Research (CiDER), Osaka University, Suita, Japan; Laboratory of Statistical Immunology, Immunology Frontier Research Center (WPI-IFReC), Osaka University, Suita, Japan.

Ryuji Koike (R)

Medical Innovation Promotion Center, Tokyo Medical and Dental University, Tokyo, Japan.

Yuko Kitagawa (Y)

Department of Surgery, Keio University School of Medicine, Tokyo, Japan.

Katsushi Tokunaga (K)

Genome Medical Science Project (Toyama), National Center for Global Health and Medicine, Tokyo, Japan.

Akinori Kimura (A)

Institute of Research, Tokyo Medical and Dental University, Tokyo, Japan.

Seiya Imoto (S)

Division of Health Medical Intelligence, Human Genome Center, the Institute of Medical Science, the University of Tokyo, Tokyo, Japan.

Satoru Miyano (S)

M&D Data Science Center, Tokyo Medical and Dental University, Tokyo, Japan.

Seishi Ogawa (S)

Department of Pathology and Tumor Biology, Kyoto University, Kyoto, Japan; Institute for the Advanced Study of Human Biology (WPI-ASHBi), Kyoto University, Kyoto, Japan; Department of Medicine, Center for Hematology and Regenerative Medicine, Karolinska Institute, Stockholm, Sweden.

Takanori Kanai (T)

Division of Gastroenterology and Hepatology, Department of Medicine, Keio University School of Medicine, Tokyo, Japan.

Koichi Fukunaga (K)

Division of Pulmonary Medicine, Department of Medicine, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH